The vitreoretinal surgeon who performed Australia’s first Luxturna gene therapy has described the intricacy of the procedure, while hailing the...
Read moreIvantis has revealed new data from its five-year HORIZON pivotal trial showing its Hydrus Microstent device lowers the rate of...
Read moreAustralian optometrists will be able to prescribe dry eye therapy lifitegrast (Xiidra) from next month without the involvement of a...
Read moreIn 2016, at his home RANZCO scientific branch meeting in Tasmania, preeminent ophthalmic genetics expert Professor Alex Hewitt presented on...
Read moreNew seven-year findings from CooperVision’s MiSight 1 day contact lens clinical trial shows no evidence of myopia control rebound in...
Read moreUS regulators have approved the country’s first presbyopia eye drop that adopts pupil constriction to improve near and intermediate vision...
Read moreThe US Food and Drug Administration (FDA) has approved the Susvimo implant which delivers ranibizumab continuously, offering patients living with...
Read moreWhen it comes to the treatment of glaucoma, there is growing evidence to suggest that the ability to re-establish the...
Read moreTeenage siblings from Sydney with an inherited retinal disease have become the first in Australia to receive the Luxturna ocular...
Read moreMelbourne researchers are developing a new gene therapy they hope will “switch on sight” by regenerating light-sensing photoreceptor cells in...
Read moreInsight has been the leading industry publication in Australia for more than 40 years. This longevity is largely due to our ability to consistently deliver accurate and independent news relevant to all ophthalmic professionals and their supporting industry.
© 2024 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited
© 2024 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited